Explain this page
Arphra AIPlain-English read on UroGen Pharma Ltd.’s valuation06-10today
- Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?5d
- UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript9d
- UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript37d
- ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial37d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $42.50 (+26.60%)
Candlestick · 1Y
Open in chart workstation →URGN
30.87+56.70%H 32.37L 16.50MA50 23.68MA200 —Avg vol 802K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.32% | +13.87% | +18.79% | +80.58% | +47.24% | +43.34% | +129.15% | +187.17% | +101.62% | +140.13% | +140.13% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$33.57
Bid
$28.44
300 sh
Ask
$34.00
80 sh
Spread
$5.560
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Technology+2.51%
- Communication Services+1.85%
- Utilities+1.35%
- Consumer Cyclical+0.30%
- Consumer Defensive-0.30%
- Energy-0.45%
- Industrials-0.48%
- Basic Materials-0.66%
- Financial Services-0.67%
- Real Estate-0.99%
- Healthcare-1.51%
Top industries (issuer's industry highlighted)
- Biotechnology+0.28%
- Oil & Gas Energy+8.53%
- Business Equipment & Supplies+5.82%
- Semiconductors+5.24%
- Electronic Gaming & Multimedia+5.23%
- Advertising Agencies-5.20%
- Medical - Equipment & Services+5.08%
- Grocery Stores-4.35%
- Financial - Mortgages+4.08%
- Broadcasting+4.00%
- Computer Hardware-3.67%
- Internet Content & Information+3.58%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?fool.com·Jun 14, 2026
- UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·Jun 10, 2026
- UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·May 13, 2026
- ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trialglobenewswire.com·May 13, 2026
- UroGen Pharma to Present at Upcoming Investor Conferencesglobenewswire.com·May 07, 2026
- UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlightsglobenewswire.com·May 06, 2026
Recent analyst activity
DB- Jun 03, 2026GradeBuy → BuyH.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)H.C. Wainwright
- Jun 02, 2026GradeOutperform → OutperformOppenheimer on UroGen Pharma (URGN): 'We expect Zusduri's continued launch to drive outperformance'Oppenheimer
Peers
No peer list available for URGN.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|